Tag Archives: Perphenazine

Alzheimer’s Therapy: Antidepressants

Overview. Major depression affects approximately 15% of Alzheimer’s disease patients. By comparison, 5-12% of the general population aged 15 years or older in the major pharmaceutical markets experience at least one episode of major depression per year. Because depression itself may lead to declines in cognition and function, treatment of depression in Alzheimer’s disease patients… Read More »

Schizophrenia: Atypical Antipsychotics

Many atypical antipsychotics are available. In addition to those reviewed in the following sections, atypical agents include perospirone (Sumitomo’s Lullan) and zotepine (Fujisawa’s Lodopin, Aventis’s Nipolept, Orion Pharma’ s Zoleptil, generics). These drugs are not discussed in detail here because their mechanisms of action are similar to those of other atypical agents, they are launched… Read More »

Dissociative [Conversion] Disorders

Description of Medical Condition A sudden change in state of consciousness, identity, motor behavior, thoughts, feelings and perception of external reality to such an extent that these functions do not operate congruently. Many pathologic symptoms can be found, but the patient experiences dysphoria, suffering, and maladaptive functioning. Disorders include: • Dissociative amnesia • Dissociative fugue… Read More »

Adjunctive Pharmacotherapy and Related Issues

Managing antipsychotic side effects. Antipsychotic drugs produce problematic side effects in many individuals (see Table Side Effects of Typical Antipsychotic Drugs). A major category of side effects results from neurotransmitter dysregulation of the extra-pyramidal motor system. It is thought that these side effects are the result of an imbalance of dopaminergic and acetylcholinergic activity in… Read More »

Psychotic Disorders in Children: Clinical Use of Antipsychotic Medications

Considerations in the Clinical Use of Antipsychotic Medications The following assertions summarize the issues discussed in this post: • Antipsychotic medications are key components in the comprehensive treatment program of severely mood dysregulated children and adolescents with psychotic symptoms, and for children and adolescents with psychotic disorders. • The second generation antipsychotics seem to offer… Read More »

Introduction To Atypical Antipsychotics

This section deals specifically with the use of atypical antipsychotics currently in use in the United States. In less than a decade, atypical antipsychotics have become the dominant force in the treatment of adult and childhood psychosis. As a result of this rapid change, the typical antipsychotics have been progressively relegated to the sidelines of… Read More »

Are Atypical Antipsychotics Better Than Conventional Antipsychotics?

Food and Drug Administration regulatory procedures assure that drugs approved for the treatment of schizophrenia have documentation of efficacy. What follows is complicated. The physician must decide which drug, at what dose, in what combination, for what period of time, for which aspect of illness, whether to use off-label and at what risk and cost.… Read More »

Use Of Atypical Antipsychotics In Aggressive Behavior

Maladaptive aggression accompanies different forms of psychopathology Affective disorders (depression, bipolar disorders), PPD, mental retardation, psychosis, PTSD, ADHD, and others can produce maladaptive aggression. The Treatment Recommendations for the use of Antipsychotics for Aggressive Youth (TRAAY) developed by the Center for the Advancement of Children’s Mental Heath and the New York State Office of Mental… Read More »

Recommendations For The Use And Selection Of Antipsychotics

1. Only one antipsychotic medication should be used at a time. Combinations of antipsychotics should not be tried until monotherapy with different available agents, including conventional antipsychotics, has been used for an extended period of time, for at least six weeks, at therapeutic doses (for each medication), or when single medications at therapeutic levels bring… Read More »

Clinical Use of Antipsychotic Medications: Medication Monitoring

Vinks and Walsons (2003) indications for therapeutic drug monitoring are listed in TABLE Factors to Attend to in Medication Monitoring. TABLE Factors to Attend to in Medication Monitoring Inadequate response Higher than standard dose required Serious and persistent side effects Suspected toxicity Suspected noncompliance Suspected drug-drug interactions New preparations, changing brands Emerging illnesses Presence of… Read More »